Visualization of von Willebrand Factor Multimers by Enzyme-Conjugated Secondary Antibodies

Summary

A method for visualization of the multimeric forms of von Willebrand Factor (vWF) in plasma and platelets is described. The method is based upon: 1) Separation of the vWF multimers by SDS-agarose electrophoresis, 2) Subsequent blotting of the vWF multimers onto nitrocellulose, 3) Immunolocalization and visualization of the vWF pattern by the sequential incubation of the blot with a) primary vWF antiserum, b) peroxidase- or beta-galactosidase-conjugated secondary antibodies and a relevant chromogenic substrate.

Key words

Von Willebrand factor (vWF) - Thrombus formation - Multimers - Visualization - Enzyme-linked antibodies

• References

• 1 Hoyer LW, Shainoff JR. Factor VUI-related protein circulates in normal human plasma as high molecular weight multimers. Blood 1980; 55: 1056-1059
• 2 Ruggeri ZM, Zimmerman TS. Variant von Willebrand’s disease: Characterization of two subtypes by analysis of multimeric composition of factor VUI/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-1325
• 13 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VUI/von Willebrand factor. Blood 1982; 57: 1140-1143
• 4 Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand Factor. J Clin Invest 1985; 76: 1491-1500
• 5 Sixma JJ, Sakariassen KS, Beeser-Visseryg NH, Ottenhof-Rovers M, Bohuis PA. Adhesion of platelets to human artery subendothelium: Effect of factor VUI-von Willebrand factor of various multimeric composition. Blood 1984; 63: 128-139
• 6 Counts RB, Paskell SL, Elgee SK. Disulfide bonds and the quaternary structure of factor VUI/von Willebrand factor. J Clin Invest 1978; 62: 702-709
• 7 Perret BA, Furlan M, Beck EA. Studies in factor VUI-related protein. II. Estimation of molecular size differences between factor VIII oligomers. Biochim Biophys Acta 1979; 578: 164-174
• 8 Meyer D, Obert B, Pietu G, Lavergne JM, Zimmerman TS. Multimeric structure of factor VUI/von Willebrand factor in von Willebrand’s disease. J Lab Clin Med 1980; 95: 590-602
• 9 Ruggeri ZM, Nilsson IM, Lombardi R, Holmberg L, Zimmerman TS. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand’s disease (type IIC). J Clin Invest 1982; 70: 1124-1127
• 10 Kinoshita S, Harrison J, Lazerson J, Abildgaard CF. A new variant of dominant type II von Willebrand’s disease with aberrant multimeric pattern of factor VUI-related antigen (type IID). Blood 1984; 63: 1369-1371
• 11 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
• 12 Allain JP, Cooper HA, Wagner RH, Brinkhouse KM. Platelets fixed with formaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 318-328
• 13 Boda Z, Solum NO, Sztaricskai F, Rak K. Study of platelet agglutination induced by the antibiotics of the vancomycin group: Ristocetin, ristomycin, actinoidin and vancomycin. Thromb Haemo-stas 1979; 42: 1164-1180
• 14 Ivy AC, Shapiro PF, Melnick P. The bleeding tendency in jaundice. Surg Gynec Obst 1935; 60: 781-784
• 15 Hjort PF, Stormorken H. A study of in vitro and in vivo effects of a synthetic heparin-like anticoagulant: Dextran sulphate. Scand J Clin Lab Invest 1957; (Suppl. 29) 13-14